https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / Cancer Res. 2004 Nov;64(21):8022-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / Cancer Res. 2004 Nov;64(21):8022-82004-11-01 00:00:002019-02-15 08:50:25Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-612004-11-01 00:00:002020-06-23 09:39:52Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / Eur J Gastroenterol Hepatol 2004 Nov;16(12):1257-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / Eur J Gastroenterol Hepatol 2004 Nov;16(12):1257-602004-11-01 00:00:002019-02-15 09:11:53The role of the immune system in the control of hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / Gastroenterology 2004 Nov;127(5 Suppl 1):S232-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / Gastroenterology 2004 Nov;127(5 Suppl 1):S232-412004-11-01 00:00:002019-02-15 09:13:24Immunotherapeutic strategies for hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / J. Immunother. 2004 Nov-Dec;27(6):452-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / J. Immunother. 2004 Nov-Dec;27(6):452-92004-11-01 00:00:002019-02-15 08:46:58Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-622004-11-01 00:00:002021-11-15 15:38:39Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-10-30 / Cancer Immunol. Immunother. 2005 Jun;54(6):587-98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-10-30 / Cancer Immunol. Immunother. 2005 Jun;54(6):587-982004-10-30 00:00:002020-06-23 09:40:23Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-10-01 / Cancer Biother. Radiopharm. 2004 Oct;19(5):658-65
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-10-01 / Cancer Biother. Radiopharm. 2004 Oct;19(5):658-652004-10-01 00:00:002019-02-15 09:19:59Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-10-01 / Cell. Mol. Immunol. 2004 Oct;1(5):351-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-10-01 / Cell. Mol. Immunol. 2004 Oct;1(5):351-62004-10-01 00:00:002004-10-01 00:00:00Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-81
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-812004-09-27 00:00:002020-06-23 09:41:00Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
